Karolinska Development appeases shareholders with $34 million deal
This article was originally published in Scrip
Sweden's Karolinska Development saw its share price jump by nearly 10% to SEK 15.00 ($2.30) by 3pm CET on 21 December, the day it announced a SEK 220 million ($33.7 million) deal to give a stake in the academic investment company's portfolio to a syndicate led by the life sciences investor Rosetta Capital.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.